189 related articles for article (PubMed ID: 24173178)
1. Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil.
Segatto MM; Dornelles SI; Silveira VB; Frantz Gde O
An Bras Dermatol; 2013; 88(5):732-8. PubMed ID: 24173178
[TBL] [Abstract][Full Text] [Related]
2. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.
Stockfleth E; Harwood CA; Serra-Guillén C; Larsson T; Østerdal ML; Skov T
Br J Dermatol; 2018 Feb; 178(2):433-442. PubMed ID: 29030864
[TBL] [Abstract][Full Text] [Related]
3. Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index.
Schmitz L; Gupta G; Segert MH; Kost R; Sternberg J; Gambichler T; Stockfleth E; Dirschka T
Skin Pharmacol Physiol; 2018; 31(4):206-211. PubMed ID: 29791916
[TBL] [Abstract][Full Text] [Related]
4. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results.
Stockfleth E; Kerl H; Zwingers T; Willers C
Br J Dermatol; 2011 Nov; 165(5):1101-8. PubMed ID: 21517801
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
[TBL] [Abstract][Full Text] [Related]
6. Topical diclofenac: new preparation. Moderate efficacy in actinic keratosis.
Prescrire Int; 2004 Aug; 13(72):138-9. PubMed ID: 15532138
[TBL] [Abstract][Full Text] [Related]
7. Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety.
Javor S; Cozzani E; Parodi A
G Ital Dermatol Venereol; 2016 Jun; 151(3):275-80. PubMed ID: 26512929
[TBL] [Abstract][Full Text] [Related]
8. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses.
Rivers JK; McLean DI
Arch Dermatol; 1997 Oct; 133(10):1239-42. PubMed ID: 9382562
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: A network meta-analysis.
Wu Y; Tang N; Cai L; Li Q
Dermatol Ther; 2019 May; 32(3):e12822. PubMed ID: 30638294
[TBL] [Abstract][Full Text] [Related]
10. A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip.
Nelson CG; Spencer J; Nelson CG
J Drugs Dermatol; 2007 Jul; 6(7):712-7. PubMed ID: 17763595
[TBL] [Abstract][Full Text] [Related]
11. In vivo Confocal Laser Microscopy for monitoring of actinic keratosis treatment: a comparison with histopathologic assessment after treatment with topical 5% 5-fluorouracil.
Ishioka P; Maia M; Rodrigues SB; Lellis RF; Hirata SH
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1155-1163. PubMed ID: 29178474
[TBL] [Abstract][Full Text] [Related]
12. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment.
Kaur RR; Alikhan A; Maibach HI
J Dermatolog Treat; 2010 Sep; 21(5):267-71. PubMed ID: 19878034
[TBL] [Abstract][Full Text] [Related]
13. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze).
Nelson C; Rigel D; Smith S; Swanson N; Wolf J
J Drugs Dermatol; 2004; 3(4):401-7. PubMed ID: 15303784
[TBL] [Abstract][Full Text] [Related]
14. Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety.
Martin GM; Stockfleth E
J Drugs Dermatol; 2012 May; 11(5):600-8. PubMed ID: 22527428
[TBL] [Abstract][Full Text] [Related]
15. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
17. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.
Nisticò S; Del Duca E; Torchia V; Gliozzi M; Bottoni U; Muscoli C
Int J Immunopathol Pharmacol; 2018; 32():2058738418757925. PubMed ID: 29442526
[TBL] [Abstract][Full Text] [Related]
18. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses.
Akarsu S; Aktan S; Atahan A; Koç P; Özkan S
Clin Exp Dermatol; 2011 Jul; 36(5):479-84. PubMed ID: 21418281
[TBL] [Abstract][Full Text] [Related]
19. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses.
Stockfleth E; Zwingers T; Willers C
Eur J Dermatol; 2012; 22(3):370-4. PubMed ID: 22494856
[TBL] [Abstract][Full Text] [Related]
20. Exacerbation of seborrheic dermatitis by topical fluorouracil.
Brodell EE; Smith E; Brodell RT
Arch Dermatol; 2011 Feb; 147(2):245-6. PubMed ID: 21339458
[No Abstract] [Full Text] [Related]
[Next] [New Search]